---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-027326"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T06:12:16.971694+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q2 revenue $861M +4% reported; EPS $1.56 -33%; cuts FY2022 guidance

## Summary
- Revenue $861M, up 4% reported and 6.5% organic; CAG Diagnostics recurring revenue +4% reported, +7% organic.
- EPS $1.56, down 33% as reported, including $0.72 impact from $80M discrete R&D investments.
- Record Q2 premium instrument placements up 18% YoY; global installed base +15%.
- Updated FY2022 revenue guidance $3,305-$3,385M (3%-5.5% reported, 5.5%-8% organic); EPS $7.77-$8.05.
- U.S. same-store clinical visits declined 3% in Q2 vs +13% prior year; diagnostics revenue +6% same-store.

## SEC filing metadata
- accession: 0001564590-22-027326
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000156459022027326/0001564590-22-027326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000156459022027326/idxx-8k_20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-027326
- JSON: https://secwatch.observer/filing/0001564590-22-027326.json
- Plain text: https://secwatch.observer/filing/0001564590-22-027326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.